

AGX Group (AGX MK)

Soaring to new heights

MALAYSIA | TRANSPORT | UPDATE

- AGX is expected to secure a substantial share of MAS' logistics requirements following its recent appointment
- All-Link's 2025E earnings are likely to undershoot our previous forecast due to near-term headwinds from US tariff disruptions
- We lower our 2025E but raise 2026–27E earnings forecasts to factor in the anticipated ramp-up in MAG contribution. Maintain BUY with higher TP of RM0.90

Major share of MAG logistics

We recently met with AGX and walked away encouraged by its growth prospects following its appointment as a service provider to Malaysia Aviation Group (MAG), handling freight forwarding and customs brokerage for aircraft parts. MAG's vendor network includes roughly 1,000 parts suppliers, compared with 300 for AirAsia, which requires greater coordination but also provides AGX with long-term operational stickiness. AGX is now expected to act as the primary provider, managing a significant share of MAG's MRO and AOG logistics, alongside one other shortlisted vendor. Previously responsible solely for AOG services, AGX's expanded scope, combined with higher fleet activity from Visit Malaysia 2026, positions the group to benefit from increased maintenance demand.

Expect MAG contribution to be in full swing 4Q26

Management expects a 6-month ramp-up period to achieve full operating efficiency. AGX currently employs 100 staff in Malaysia and anticipates only a 10–20% increase in headcount, demonstrating the scalability of its operations with minimal incremental costs. Margins from MAG are expected to be broadly in line with other airline customers, alleviating concerns over margin dilution despite higher operational complexity. Management indicated that MAG's earnings contribution could eventually be comparable to AirAsia's. In our base case, we assume MAG contributes c.11% of group revenue in FY27E, reflecting AGX's growing role within the logistics ecosystem.

Maintain BUY call with a higher 12-month TP of RM0.90 (from RM0.85)

We trim our 2025E EPS by 17% to reflect near-term headwinds from US tariff disruptions affecting All-Link contribution. Conversely, we raise our 2026–27E estimate by 6–14% to incorporate MAG's contribution. Our 12-month TP is raised to RM0.90, based on unchanged target 2026E PER of 12x. Maintain BUY. Overall, AGX's stronger earnings visibility underpinned by a projected 3-year CAGR of 43% provides a clear catalyst for potential re-rating as MAG's contribution materialise.

Key Financials

Y/E Dec	2023	2024	2025E	2026E	2027E
Revenue (RMm)	186.8	238.4	268.0	380.9	453.7
EBITDA (RMm)	19.3	10.5	21.0	36.3	43.0
Pretax profit (RMm)	12.8	15.4	23.6	38.6	46.0
Net profit (RMm)	8.4	12.9	20.5	32.4	38.5
EPS (sen)	1.9	3.0	4.7	7.5	8.9
PER (x)	28.7	18.6	11.7	7.4	6.2
Core net profit (RMm)	8.5	13.3	20.5	32.4	38.5
Core EPS (sen)	2.0	3.1	4.7	7.5	8.9
Core EPS growth (%)	(37.9)	55.8	53.6	58.2	19.0
Core PER (x)	28.1	18.0	11.7	7.4	6.2
Net DPS (sen)	0.0	0.0	0.0	0.0	0.0
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0
EV/EBITDA (x)	10.0	11.7	10.5	7.1	4.4
Chg in EPS (%)		-	(16.6)	+5.6	+13.5
Phillip/Consensus (%)			1.0	1.3	1.4

Sources: Company, Bloomberg, Phillip Research forecasts

9 February 2026

BUY (maintain)

LAST CLOSE PRICE	RM0.56
TARGET PRICE	RM0.90
TOTAL RETURN	62.2%
(PREVIOUS TP:	RM0.85)

COMPANY DATA

BLOOMBERG TICKER	AGX MK EQUITY
O/S SHARES (MN) :	433
MARKET CAP (USD mn / RM mn) :	62 / 242
52 - WK HI/LO (RM) :	0.63 / 0.41
3M Average Daily T/O (mn) :	0.24
NET CASH/(DEBT) (RMm)	(22.20)


MAJOR SHAREHOLDERS (%)

Mark Penu	19.1%
Neo Lip Pheng	18.1%
Gopal Jayasielan	11.5%

PRICE PERFORMANCE (%)

	1MTH	3MTH	YTD
COMPANY	6.7	23.3	18.1
FBMKLCI RETURN	2.7	7.0	3.1

PRICE VS. FBMKLCI



Source: Bloomberg

Jin Wei LAM

lam.jinwei@phillipcapital.com.my

Jianyuan TAN, FCCA

tan.jianyuan@phillipcapital.com.my

Rapid fleet expansion. AGX's aerospace logistics segment has historically relied on AirAsia Group, servicing 242 aircraft in 2024. Fleet coverage increased to 365 aircraft by end-25 with VietJet Air and Sun Phu Quoc Airways onboarded. The subsequent addition of MAG's 90 aircraft under a service agreement, alongside servicing exposure to Philippine Airlines' 79 aircraft, lifted AGX's total serviced fleet to 534 aircraft. This translates into a 121% growth in fleet coverage reflecting AGX's strong execution and clear growth visibility. In addition, AGX has identified 753 aircraft across regional airlines as potential onboarding opportunities, supporting a clear long-term growth trajectory in ASEAN.

Table 1: AGX existing customers' fleet

Table 2: AGX current countries presence




Source: Company

Source: Company


Trim 2025E EPS by 17%, but raise 2026 – 27E by 6-14%. We expect weaker-than-anticipated 4Q25 earnings as US tariff disruptions dampened order flows and weighed on All-Link contributions. Accordingly, we revise our 2025E EPS down by 17%. Looking ahead, we are more bullish on 2026–27E earnings, forecasting a 19-58% YoY increase in core net profit. A clearer recovery is expected from 2026E onwards as tariff pressures ease and the broader macro environment normalises. Incorporating MAG's contribution, we raise our 2026–27E EPS estimates by 6–14%.

Table 3: Raising our revenue forecasts to factor in MAG contributions

Table 4: Revision made to our 2025–27E earnings forecasts




Source: Phillip Research forecasts



Source: Phillip Research forecasts

Table 5: AGX revenue and profit forecasts




Source: Company, Phillip Research forecasts

AirAsia remains as AGX's core revenue pillar. AirAsia Group has historically been a key revenue contributor to AGX's total group revenue, accounting for 17-28% of 2023–24 revenue and estimated to account for 20% of 2025E revenue. We estimate that MAG will account for 11% of group revenue in 2027E as AGX fully ramp up its MRO and AOG logistic operations. Consequently, AirAsia's share of total revenue is expected to decline to 11% (2024: 17%). While AirAsia's revenue share decreased in percentage terms, absolute revenue is still projected to grow. The shift in revenue mix reflects broader customer diversification and incremental revenue streams, which we view positively as it enhances AGX's revenue resilience and reduces customer concentration risk.

Maintain BUY with a higher target price of RM0.90. All in, we maintain our BUY rating on AGX with a higher 12-month target price of RM0.90 (from RM0.85), based on an unchanged target 12x PE multiple on 2026E EPS. Despite a weaker-than-expected 2025E earnings trajectory due to tariff disruptions impacting All Link's contribution, we expect earnings growth to accelerate in 2026–27E. AGX is currently trading at a forward 7.4x 2026E PE, which we view as attractive given the strong earnings visibility. The earnings trajectory is supported both by contributions from existing businesses and the incremental impact from MAG, which could drive further valuation re-rating.

Key downside risks include lower-than-expected freight demand, decline in freight rates, and loss of customers.

Table 6: AGX PE chart since listing



Source: Bloomberg, Phillip Research forecasts

FINANCIALS

Income Statement

Y/E Dec (RMm)	2023	2024	2025E	2026E	2027E
Revenue	187	238	268	381	454
Operating expenses	(167)	(228)	(247)	(345)	(411)
EBITDA	19	10	21	36	43
Depreciation	(6)	(4)	(7)	(10)	(11)
EBIT	13	6	14	27	32
Net int income/(expense)	(1)	(2)	(2)	(2)	(2)
Exceptional gains / (losses)	0	0	0	0	0
Associates' contribution	1	12	11	14	16
Pretax profit	13	15	24	39	46
Tax	(4)	(3)	(3)	(6)	(8)
Minority interest	0	0	0	0	0
Net profit	8	13	20	32	39
Core net profit	9	13	20	32	39

Balance sheet

Y/E Dec (RMm)	2023	2024	2025E	2026E	2027E
Fixed assets	4	32	35	43	47
Other long term assets	15	16	16	16	16
Total non-current assets	19	48	50	58	62
Cash and equivalents	10	16	21	29	42
Stocks	0	0	0	0	0
Debtors	66	75	84	119	142
Other current assets	4	13	13	13	13
Total current assets	80	104	118	162	198
Creditors	21	23	25	35	42
Short term borrowings	14	8	8	8	8
Other current liabilities	6	8	8	8	8
Total current liabilities	41	40	42	52	58
Long term borrowings	0	1	1	1	1
Other long term liabilities	7	22	34	36	48
Total long term liab.	7	22	34	36	49
Shareholders' Funds	51	90	92	132	153
Minority Interest	0	0	0	0	0

Cash Flow Statement

Y/E Dec (RMm)	2023	2024	2025E	2026E	2027E
Pretax Profit	13	15	24	39	46
Depreciation & amortisation	6	4	7	10	11
Working capital changes	(14)	(12)	(7)	(25)	(16)
Cash tax paid	(4)	(5)	(3)	(6)	(8)
Others	2	2	(11)	(4)	(16)
C/F from operation	3	4	9	13	18
Capex	(1)	(5)	(2)	(3)	(3)
Others	3	2	(1)	(1)	(1)
C/F from investing	2	(2)	(3)	(3)	(3)
Debt raised/(repaid)	(3)	(12)	0	0	0
Dividends paid	(7)	(4)	0	0	0
Others	(1)	33	(1)	(1)	(1)
C/F from financing	(11)	17	(1)	(1)	(1)
Net change in cash flow	(6)	19	5	8	13
Free Cash Flow	2	(0)	7	10	15

Source: Company, Phillip Research forecasts

Financial Ratios and Margins

Y/E Dec (RMm)	2023	2024	2025E	2026E	2027E
Growth					
Revenue (%)	(20.3)	27.6	12.4	42.1	19.1
EBITDA (%)	6.4	(45.8)	99.9	73.2	18.4
Core net profit (%)	(37.9)	55.8	53.6	58.2	19.0
Profitability					
EBITDA margin (%)	10.4	4.4	7.8	9.5	9.5
PBT margin (%)	6.9	6.5	8.8	10.1	10.1
Core net profit margin (%)	4.6	5.6	7.6	8.5	8.5
Effective tax rate (%)	39.6	69.8	25.0	25.0	25.0
ROA (%)	9.0	10.3	12.8	16.7	16.0
Core ROE (%)	17.9	18.9	22.5	28.8	27.1
ROCE (%)	21.8	7.6	14.3	22.1	21.0
Dividend payout ratio (%)	0	0	0	0	0
Liquidity					
Current ratio (x)	2.0	2.6	2.8	3.1	3.4
Op. cash flow (RMm)	3	4	9	13	18
Free cashflow (RMm)	2	0	7	10	15
FCF/share (sen)	1	0	2	2	3
Asset management					
Debtors turnover (days)	128	114	114	114	114
Stock turnover (days)	0	0	0	0	0
Creditors turnover (days)	46	38	38	37	37
Capital structure					
Net gearing (%)	7%	-7%	-13%	-15%	-22%
Interest cover (x)	10.1	9.1	2.9	8.5	16.0

Quarterly Profit & Loss

Y/E Dec (RMm)	3Q24	4Q24	1Q25	2Q25	3Q25
Revenue	66	67	62	70	73
Operating expenses	(60)	(62)	(55)	(62)	(67)
EBITDA	6	4	7	8	6
Depreciation	(2)	(3)	(3)	(3)	(3)
EBIT	4	1	4	5	3
Int income	0	0	0	0	0
Int expense	(1)	(1)	(1)	(1)	(1)
Associates' contribution	2	8	3	2	3
Exceptional items	(3)	(1)	(1)	(1)	(0)
Pretax profit	3	8	5	5	5
Tax	(1)	(1)	(1)	(1)	(1)
Minority interest	0	0	0	0	0
Net profit	2	7	5	4	4
Core net profit	5	8	6	5	5
Margins (%)					
EBITDA	9.5	6.5	10.9	11.0	8.4
PBT	4.6	11.8	8.6	7.4	7.0
Net profit	3.6	10.8	7.3	5.9	5.8

Contact Information (Regional Member Companies)
SINGAPORE

Phillip Securities Pte Ltd
 Raffles City Tower
 250, North Bridge Road #06-00
 Singapore 179101
 Tel +65 6533 6001
 Fax +65 6535 6631
 Website: www.poems.com.sg

JAPAN

Phillip Securities Japan, Ltd.
 4-2 Nihonbashi Kabuto-cho Chuo-ku,
 Tokyo 103-0026
 Tel +81-3 3666 2101
 Fax +81-3 3666 6090
 Website: www.phillip.co.jp

THAILAND

Phillip Securities (Thailand) Public Co. Ltd
 15th Floor, Vorawat Building,
 849 Silom Road, Silom, Bangrak,
 Bangkok 10500 Thailand
 Tel +66-2 6351700 / 22680999
 Fax +66-2 22680921
 Website: www.phillip.co.th

UNITED STATES

Phillip Capital Inc
 141 W Jackson Blvd Ste 3050
 The Chicago Board of Trade Building
 Chicago, IL 60604 USA
 Tel +1-312 356 9000
 Fax +1-312 356 9005
 Website: www.phillipusa.com

INDIA

PhillipCapital (India) Private Limited
 No.1, 18th Floor, Urmi Estate
 95, Ganpatrao Kadam Marg
 Lower Parel West, Mumbai 400-013
 Maharashtra, India
 Tel:+91-22-2300 2999/Fax:+91-22-2300 2969
 Website: www.phillipcapital.in

MALAYSIA

Phillip Capital Sdn Bhd
 B-18-6 Block B Level 18 Unit 6 Megan Avenue II,
 No .12, Jalan Yap Kwan Seng, 50450 Kuala
 Lumpur
 Tel +603 2783 0300
 Fax +603 2166 5099
 Website: www.phillip.com.my

INDONESIA

PT Phillip Securities Indonesia
 ANZ Tower Level 23B,
 Jl Jend Sudirman Kav 33A
 Jakarta 10220 – Indonesia
 Tel +62-21 5790 0800
 Fax +62-21 5790 0809
 Website: www.phillip.co.id

FRANCE

King & Shaxson Capital Limited
 3rd Floor, 35 Rue de la Bienfaisance 75008
 Paris France
 Tel +33-1 45633100
 Fax +33-1 45636017
 Website: www.kingandshaxson.com

AUSTRALIA

Phillip Capital Limited
 Level 10, 330 Collins Street
 Melbourne, Victoria 3000, Australia
 Tel +61-03 8633 9803
 Fax +61-03 8633 9899
 Website: www.phillipcapital.com.au

TURKEY

PhillipCapital Menkul Degerler
 Dr. Cemil Bengü Cad. Hak Is Merkezi
 No. 2 Kat. 6A Caglayan
 34403 Istanbul, Turkey
 Tel: 0212 296 84 84
 Fax: 0212 233 69 29
 Website: www.phillipcapital.com.tr

HONG KONG

Phillip Securities (HK) Ltd
 11/F United Centre 95 Queensway
 Hong Kong
 Tel +852 2277 6600
 Fax +852 2868 5307
 Websites: www.phillip.com.hk

CHINA

Phillip Financial Advisory (Shanghai) Co Ltd
 No 550 Yan An East Road,
 Ocean Tower Unit 2318,
 Postal code 200001
 Tel +86-21 5169 9200
 Fax +86-21 6351 2940
 Website: www.phillip.com.cn

UNITED KINGDOM

King & Shaxson Capital Limited
 6th Floor, Candlewick House,
 120 Cannon Street,
 London, EC4N 6AS
 Tel +44-20 7426 5950
 Fax +44-20 7626 1757
 Website: www.kingandshaxson.com

CAMBODIA

Phillip Bank Plc
 Ground Floor of B-Office Centre, #61-64,
 Norodom Blvd Corner Street 306, Sangkat
 Boeung Keng Kang 1, Khan Chamkamorn,
 Phnom Penh, Cambodia
 Tel: 855 (0) 7796 6151/855 (0) 1620 0769
 Website: www.phillipbank.com.kh

DUBAI

Phillip Futures DMCC
 Member of the Dubai Gold and
 Commodities Exchange (DGCX)
 Unit No 601, Plot No 58, White Crown Bldg,
 Sheikh Zayed Road, P.O.Box 212291
 Dubai-UAE
 Tel: +971-4-3325052 / Fax: + 971-4-3328895

Contact Information (Phillip Malaysia Investor Centres)

MALAYSIA

Phillip Investor Centre – Alor Setar (Kedah)

Lot T-30 2nd Floor,
Wisma PKNK, Jalan Sultan Badlisha,
05000 Alor Setar, Kedah
Tel: +604 731 7088 / Fax: 604 731 8428
Website: www.phillip.com.my

MALAYSIA

Phillip Investor Centre – Kluang (Johor)

No. 73, 1st Floor,
Jalan Rambutan, 86000 Kluang.
Tel: +607 771 7922 / Fax: 607 771 7909
Website: www.phillip.com.my

MALAYSIA

Phillip Investor Centre – Kuantan (Pahang)

1st Floor, B400,
Jalan Beserah, 25300 Kuantan.
Tel: +609 566 0800 / Fax: 609 566 0801
Website: www.phillip.com.my

MALAYSIA

Phillip Investor Centre – Kuching (Sarawak)

Lot 2650 1st Floor, Suite A, Block 10 KCLD
Central Park Commercial Centre,
3rd Mile, Jalan Rock, 93200, Kuching,
Sarawak, Malaysia.
Tel: +6082 247 633 / Fax: 6082 245 644
Website: www.phillip.com.my

MALAYSIA

Phillip Investor Centre – Johor Bahru (Johor)

15-01A, Jalan Molek 1/29,
Taman Molek, 81100 Johor Bahru,
Johor Darul Takzim, Malaysia
Tel: +607 352 1808 / Fax: 607 352 4808
Website: www.phillip.com.my

MALAYSIA

Phillip Investor Centre – Kota Damansara (Petaling Jaya)

12A, Jalan PJU 5/8,
Dataran Sunway, Kota Damansara,
47810 Petaling Jaya, Selangor, Malaysia.
Tel: +603 9212 2818 / Fax: 603 6140 7133
Website: www.phillip.com.my

MALAYSIA

Phillip Investor Centre – Melaka

No. 542A, Jalan Merdeka,
Taman Melaka Raya,
75000 Melaka, Malaysia
Tel: +606 292 0018 / Fax: 606 292 4511
Website: www.phillip.com.my

MALAYSIA

Phillip Investor Centre – Sibü (Sarawak)

No. 6B Jalan Bako,
96000 Sibü, Sarawak.
Tel: +6084 377 933 / Fax: -
Website: www.phillip.com.my

MALAYSIA

Phillip Investor Centre – Skudai (Johor)

9A, Jalan Sutera Tanjung 8/2,
Taman Sutera Utama,
81300 Skudai, Johor, Malaysia.
Tel: +607 557 2188 / Fax: 607 557 8788
Website: www.phillip.com.my

MALAYSIA

Phillip Investor Centre – Kota Kinabalu (Sabah)

Lot No. G-4, Ground Floor,
Menara MAA, No 6, Lorong Api-Api 1,
88000 Kota Kinabalu, Sabah.
Tel: +6088 335 346 / Fax: -
Website: www.phillip.com.my

MALAYSIA

Phillip Investor Centre – Penang

No. 29A Ground Floor Suite 2, Beach Street,
10300 Penang, Malaysia.
Tel: +604 202 0039 / Fax: 607 261 3822
Website: www.phillip.com.my

Disclaimers

Legal and Regulatory Notices (Electronic Communications)

© 2018 PRSB.

Important disclosures

This research report is strictly confidential and has been prepared for information purposes only by Phillip Research Sdn Bhd ("PRSB"), a subsidiary of Phillip Capital Holdings Sdn Bhd ("PCH") and is meant for circulation to its clients and clients of other subsidiaries companies of PCH particularly Phillip Mutual Berhad ("PMB"), Phillip Capital Management Sdn Bhd ("PCM"), Phillip Wealth Planners Sdn Bhd ("PWP") and Phillip Capital Sdn Bhd ("PCSB") (collectively refer to as Phillip Group other licensed intermediaries ("PGOLI")) only or such other persons as may be deemed eligible to receive such research report, information or opinion contained herein. Neither the publication/communication nor any portion hereof may be reprinted, distributed, sold, resold, redistributed, copied, reproduced, published, republished, displayed, posted or transmitted in any form or media or by any means without the written consent of PRSB.

The policy of PRSB is to only publish research that is impartial, independent, clear, fair, and not misleading. Analysts never receive compensation from companies they cover. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure is for your information only and does not constitute any recommendation, representation or warranty. Absence of a disclosable position should not be taken as endorsement on the validity or quality of the research report or recommendation.

To maintain the independence and integrity of PRSB's research, PGOLI activities such as fund management, dealing in securities (restricted to unit trust and private retirement scheme), dealing in derivatives, clearing for derivatives, financial planning and research business lines are distinct from one another. This means that PRSB is not part of and does not report to any of PGOLI. Accordingly, PGOLI does not supervise nor control the activities of PRSB's research analysts. PRSB's research analysts report to the Head of Research, who in turn report to PRSB's senior management.

PRSB and PGOLI have in place internal controls designed to manage conflicts of interest that may arise as a result of PGOLI engaging in fund management, dealing in securities (restricted to unit trust and private retirement scheme), dealing in derivatives, clearing for derivatives, financial planning and PRSB activities. Some examples of these controls include: the use of information barriers and other information controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with PRSB and PGOLI's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among PRSB's research personnel, fund management, dealing in securities (restricted to unit trust and private retirement scheme), dealing in derivatives, clearing for derivatives, and financial planning, PGOLI's financial product issuers and PRSB's research analysts do not compromise the integrity and independence of PRSB's research.

Neither analysts nor their household members/associates/may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a pre-existing holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities up to the date of the publication of this research report.

Unless specified otherwise, PRSB did not receive investment banking/non-investment banking income from, and did not manage/co-manage a public offering for, the listed company during the past 12 months, and it does not expect to receive investment banking compensation from the listed company within the coming three months. Unless mentioned otherwise, PRSB does not own a material disclosable position, and does not make a market, in the securities.

We hereby certify that the views expressed in this research report accurately reflect our views about the securities and/or the issuers and that no part of our compensation were or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. We hereby confirm that our analyst(s) has/have not been placed under any undue influence, intervention or pressure by any person(s) in compiling this research report. This report is prepared without any intention to raise, lower or maintaining the price of the securities covered or to induce the recipient to buy or sell the securities covered. In addition, our analyst(s) included herein attest that he/she/they was/were not in possession of any material, non-public price sensitive information regarding the subject company at the time of publication of the report. Save from the disclosure below (if any), we are not aware of any material conflict of interest.

PRSB Investment and Sector Definition:

Equity:

BUY: Total stock return expected to exceed +10% over 12-month period

HOLD: Total stock return to be between -10% and +10% over a 12-month period

SELL: Total stock return is expected to below 10% over a 12-month period

Sector:

OVERWEIGHT: The sector is expected to outperform the overall FBMKLCI over the next 12 months

NEUTRAL: The sector is to perform in line with the overall FBMKLCI market over the next 12 months

UNDERWEIGHT: The sector is expected to underperform the overall FBMKLCI market over the next 12 months

For a history of the recommendations and price targets for companies mentioned in this report, as well as company specific disclosures, please write to: Phillip Research Sdn Bhd, B-18-6, Block B Level 18, Megan Avenue II, 12 Jalan Yap Kwan Seng, 50450 Kuala Lumpur, Malaysia.

The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject PRSB and/or its associate companies to any additional registration or licensing requirement within such jurisdiction. The information and statistical data herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and we make no representation or warranty as to its accuracy, completeness or correctness. Any opinions or estimates herein reflect the judgment of PRSB at the date of this publication/communication and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person (include but not limited to Financial Planners and Marketing Representative or a non-analyst), such views and opinions may not correspond to the published view of PRSB. This is not a solicitation or any offer to buy or sell. This publication/communication is for information purposes only and does not constitute any recommendation, representation, warranty or guarantee of performance. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors.

This is not intended to provide professional, investment or any other type of advice or recommendation and does not take into account the particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this publication/communication, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including tax advice. PRSB, and PGOLI do not accept any responsibility and cannot be held liable for any person's use of, or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, PRSB accepts no liability whatsoever for any direct or consequential loss arising from the use of this publication/communication or its contents. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion about the non-rated companies.

Subject to any applicable laws and regulations at any given time, PRSB, PGOLI and their respective affiliates or companies or individuals connected with PRSB may have used the information contained herein before publication and may have positions in, may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided investment banking, capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, investors should be aware that PRSB, PGOLI and/or their respective affiliates or companies or such individuals may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the disclosable interest can be found in certain reports as required by the relevant rules and regulation. Disclosures therein include the position of PRSB and PGOLI only. Unless specified otherwise, PRSB did not receive any compensation or other benefits from the subject company covered in this publication/communication.

The analysts/contributors to this publication/communication may be employed by any relevant PGOLI entity, which is different from the entity that distributes the publication/communication in the respective jurisdictions.

PRSB, PGOLI and/or its officers, directors and employees, may, to the extent permitted by applicable law and/or regulation, deal as principal, agent, or otherwise, or have long or short positions in, or buy or sell, the securities, commodities or instruments, or options or other derivative instruments based thereon, of issuers or securities mentioned herein. PGOLI may also act as market maker or liquidity provider (within the meaning of applicable regulations in the UK) in the financial instruments of the issuer. Where the activity of market maker is carried out in accordance with the definition given to it by specific laws and regulations of the US or other jurisdictions, this will be separately disclosed within the specific issuer disclosures.

Investors should not consider this report as only a single factor in making their investment decision and, as such, the report should not be viewed as identifying or suggesting all risks, direct or indirect, that may be associated with any investment decision. PRSB produces a number of different types of research product including, among others, fundamental analysis and quantitative analysis; recommendations contained in one type of research product may differ from recommendations contained in other types of research product, whether as a result of differing time horizons, methodologies or otherwise. PRSB and PGOLI publishes research product in a number of different ways including the posting of product on the PGOLI portals and/or distribution directly to clients. Different groups of clients may receive different products and services from the research department depending on their individual requirements.

Figures presented herein may refer to past performance or simulations based on past performance which are not reliable indicators of future performance. Where the information contains an indication of future performance, such forecasts may not be a reliable indicator of future performance. Moreover, simulations are based on models and simplifying assumptions which may oversimplify and not reflect the future distribution of returns. Any figure, strategy or index created and published for illustrative purposes within this report is not intended for "use" as a "benchmark".

Certain securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment.

With respect to Fixed Income Research: Recommendations fall into two categories: tactical, which typically last up to three months; or strategic, which typically last from 6-12 months. However, trade recommendations may be reviewed at any time as circumstances change. 'Stop loss' levels for trades are also provided; which, if hit, closes the trade recommendation automatically. Prices and yields shown in recommendations are taken at the time of submission for publication and are based on either indicative Bloomberg, Reuters or PGOLI prices or yields at that time. The prices and yields shown are not necessarily those at which the trade recommendation can be implemented.

The securities described herein may not have been registered under the US Securities Act of 1933 (the '1933 Act'), and, in such case, may not be offered or sold in the US or to US persons unless they have been registered under the 1933 Act, or except in compliance with an exemption from the registration requirements of the 1933 Act. Unless governing law permits otherwise, any transaction should be executed via PhillipCapital Group entity in your home jurisdiction.